Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Original Article
R. Motzer, B. Alekseev, S.-Y. Rha, C. Porta, M. Eto, T. Powles, V. Grünwald, T.E. Hutson, E. Kopyltsov, M.J. Méndez-Vidal, V. Kozlov, A. Alyasova, S.-H. Hong, A. Kapoor, T.A. Gordoa, J.R. Merchan, E. Winquist, P. Maroto, J.C. Goh, M. Kim, H. Gurney, V. Patel, A. Peer, G. Procopio, T. Takagi, B. Melichar, F. Rolland, U.D. Giorgi, S. Wong, J. Bedke, M. Schmidinger, C.E. Dutcus, A.D. Smith, L. Dutta, K. Mody, R.F. Perini, D. Xing, and T.K. Choueiri
N Engl J Med 2021;384:1289-1300
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Saturday, April 8, 2023 - 11:59pm.